UNSPSC 51422401: 11-deoxycortisol or cortexolone or cortodoxone

This classification denotes a therapeutic glucocorticoid with the molecular formula C21H30O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WDT5SLP0HQ, chemically known as 17,21-dihydroxyprogesterone but generally known as 11-desoxy-17-hydroxycorticosterone, which bears US NIH Compound Identifier 9050. European Medicines Agency schedules Cortodoxone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06810MIG. The term 11-DESOXY-17-HYDROXYCORTICOSTERONE is an International Non-Proprietary Name.

SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)CC2)CC1)C)C(=O)CO.

UNSPSC 51422401 11-deoxycortisol or cortexolone or cortodoxone is a Commodity code that shows limited alignment with recent state and local procurement activity. The single recent opportunity posted under this code — Seminole County, Florida's IFB60459723LAS for naloxone and drug deactivation systems — concerns pharmaceutical supplies and medical emergency response products, not the steroid compounds the code nominally describes. State and local governments do source pharmaceutical and medical supplies through UNSPSC categories, but the mismatch between the code's stated scope and the actual procurement suggests either a tagging error in the opportunity database or that this particular Commodity code is not in active use for state and local buying.

Seminole County's July 2026 solicitation sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, on an IFB basis with a response deadline of July 26, 2023. The contract carried a two-year initial term with one-year renewal option, E-Verify compliance and drug-free workplace certification requirements, and potential FEMA funding with associated federal compliance obligations. No explicit set-aside or disadvantaged-enterprise designation was noted. The limited recent activity and the categorical mismatch indicate this code warrants low priority for business development unless your firm actively pursues pharmaceutical or medical-supply contracts with Florida counties and can clarify whether tagging inconsistencies reflect genuine procurement demand.